Page 46 - MI-2-1

Microbes & Immunity iPSC-derived NK cell immunotherapy

Proc Natl Acad Sci U S A. 1996;93(22):12445-12450. macrophages induces the resistance of prostate cancer cells to
cytotoxic action of NK cells. Exp Cell Res. 2018;364(1):113-123.
doi: 10.1073/pnas.93.22.12445
doi: 10.1016/j.yexcr.2018.01.041
19. Nahi H, Chrobok M, Meinke S, et al. Autologous NK cells as
consolidation therapy following stem cell transplantation in 30. Crane CA, Austgen K, Haberthur K, et al. Immune evasion
multiple myeloma. Cell Rep Med. 2022;3(2):100508. mediated by tumor-derived lactate dehydrogenase induction
of NKG2D ligands on myeloid cells in glioblastoma patients.
doi: 10.1016/j.xcrm.2022.100508
Proc Natl Acad Sci. 2014;111(35):12823-12828.
20. Martínez-Sánchez MV, Fuster JL, Campillo JA, et al.
Expression of NK cell receptor ligands on leukemic cells is doi: 10.1073/pnas.1413933111
associated with the outcome of childhood acute leukemia. 31. Gao Y, Souza-Fonseca-Guimaraes F, Bald T, et al. Tumor
Cancers. 2021;13(10):2294. immunoevasion by the conversion of effector NK
cells into type 1 innate lymphoid cells. Nat Immunol.
doi: 10.3390/cancers13102294
2017;18(9):1004-1015.
21. Xue Z, Gao Y, Wu X. Anti-Relapse effects of donor natural
killer cells and IL-2 gene modification on allogeneic doi: 10.1038/ni.3800
hematopoietic stem cell transplantation in acute leukemia. 32. Fujisaki H, Kakuda H, Shimasaki N, et al. Expansion of
Cancer Biomark. 2020;29(2):207-219. highly cytotoxic human natural killer cells for cancer cell
therapy. Cancer Res. 2009;69(9):4010-4017.
doi: 10.3233/cbm-191296
doi: 10.1158/0008-5472.CAN-08-3712
22. Yano M, Sharpe C, Lance JR, et al. Evaluation of allogeneic
and autologous membrane-bound IL-21-expanded NK 33. Liu E, Marin D, Banerjee P, et al. Use of CAR-transduced
cells for chronic lymphocytic leukemia therapy. Blood Adv. natural killer cells in CD19-positive lymphoid tumors.
2022;6(20):5641-5654. N Engl J Med. 2020;382(6):545-553.
doi: 10.1182/bloodadvances.2021005883 doi: 10.1056/NEJMoa1910607

23. Ruggeri L, Capanni M, Urbani E, et al. Effectiveness of donor 34. Yu M, Luo H, Fan M, et al. Development of GPC3-specific
natural killer cell alloreactivity in mismatched hematopoietic chimeric antigen receptor-engineered natural killer cells
transplants. Science. 2002;295(5562):2097-2100. for the treatment of hepatocellular carcinoma. Mol Ther.
2018;26(2):366-378.
doi: 10.1126/science.1068440
doi: 10.1016/j.ymthe.2017.12.012
24. Cai L, Zhang Z, Zhou L, et al. Functional impairment
in circulating and intrahepatic NK cells and relative 35. Hesslein DG, Lanier LL. Transcriptional control of natural
mechanism in hepatocellular carcinoma patients. Clin killer cell development and function. Adv Immunol.
Immunol. 2008;129(3):428-437. 2011;109:45-85.
doi: 10.1016/j.clim.2008.08.012 doi: 10.1016/B978-0-12-387664-5.00002-9
25. Fathy A, Eldin MM, Metwally L, Eida M, Abdel-Rehim M. 36. Deng Y, Kerdiles Y, Chu J, et al. Transcription factor foxo1
Diminished absolute counts of CD56dim and CD56bright is a negative regulator of natural killer cell maturation and
natural killer cells in peripheral blood from Egyptian function. Immunity. 2015;42(3):457-470.
patients with hepatocellular carcinoma. Egypt J Immunol. doi: 10.1016/j.immuni.2015.02.006
2009;16(2):17-25.
37. Zhang Q, Bi J, Zheng X, et al. Blockade of the checkpoint
26. Estrella V, Chen T, Lloyd M, et al. Acidity generated by the receptor TIGIT prevents NK cell exhaustion and elicits potent
tumor microenvironment drives local invasion. Cancer Res. anti-tumor immunity. Nat Immunol. 2018;19(7):723-732.
2013;73(5):1524-1535.
doi: 10.1038/s41590-018-0132-0
doi: 10.1158/0008-5472.Can-12-2796
38. Sutlu T, Nystrom S, Gilljam M, Stellan B, Applequist SE,
27. Bhandari V, Hoey C, Liu LY, et al. Molecular landmarks Alici E. Inhibition of intracellular antiviral defense
of tumor hypoxia across cancer types. Nature Genet. mechanisms augments lentiviral transduction of human
2019;51(2):308-318.
natural killer cells: Implications for gene therapy. Hum Gene
doi: 10.1038/s41588-018-0318-2 Ther. 2012;23(10):1090-1100.
28. Zheng X, Qian Y, Fu B, et al. Mitochondrial fragmentation doi: 10.1089/hum.2012.080
limits NK cell-based tumor immunosurveillance. Nat 39. Schuster SJ, Svoboda J, Chong EA, et al. Chimeric antigen
Immunol. 2019;20(12):1656-1667.
receptor T cells in refractory B-cell lymphomas. N Engl J
doi: 10.1038/s41590-019-0511-1 Med. 2017;377(26):2545-2554.
29. Xu L, Shen M, Chen X, et al. In vitro-induced M2 type doi: 10.1056/NEJMoa1708566

Volume 2 Issue 1 (2025) 38 doi: 10.36922/mi.5653